A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection
Friederike Langhauser, Ana I Casas, Vu-Thao-Vi Dao, Emre Guney, Jörg Menche, Eva Geuss, Pamela W M Kleikers, Manuela G López, Albert-L Barabási, Christoph Kleinschnitz, Harald H H W Schmidt, Friederike Langhauser, Ana I Casas, Vu-Thao-Vi Dao, Emre Guney, Jörg Menche, Eva Geuss, Pamela W M Kleikers, Manuela G López, Albert-L Barabási, Christoph Kleinschnitz, Harald H H W Schmidt
Abstract
Network medicine utilizes common genetic origins, markers and co-morbidities to uncover mechanistic links between diseases. These links can be summarized in the diseasome, a comprehensive network of disease-disease relationships and clusters. The diseasome has been influential during the past decade, although most of its links are not followed up experimentally. Here, we investigate a high prevalence unmet medical need cluster of disease phenotypes linked to cyclic GMP. Hitherto, the central cGMP-forming enzyme, soluble guanylate cyclase (sGC), has been targeted pharmacologically exclusively for smooth muscle modulation in cardiology and pulmonology. Here, we examine the disease associations of sGC in a non-hypothesis based manner in order to identify possibly previously unrecognized clinical indications. Surprisingly, we find that sGC, is closest linked to neurological disorders, an application that has so far not been explored clinically. Indeed, when investigating the neurological indication of this cluster with the highest unmet medical need, ischemic stroke, pre-clinically we find that sGC activity is virtually absent post-stroke. Conversely, a heme-free form of sGC, apo-sGC, was now the predominant isoform suggesting it may be a mechanism-based target in stroke. Indeed, this repurposing hypothesis could be validated experimentally in vivo as specific activators of apo-sGC were directly neuroprotective, reduced infarct size and increased survival. Thus, common mechanism clusters of the diseasome allow direct drug repurposing across previously unrelated disease phenotypes redefining them in a mechanism-based manner. Specifically, our example of repurposing apo-sGC activators for ischemic stroke should be urgently validated clinically as a possible first-in-class neuroprotective therapy.
Conflict of interest statement
H.H.H.W.S. receive a research grant from Bayer Healthcare, the patent owner of BAY58-2667 and BAY60-2770. The remaining authors declare no competing financial interests.
Figures
References
- O’Collins VE, et al. 1,026 experimental treatments in acute stroke. Ann. Neurol. 2006;59:467–477. doi: 10.1002/ana.20741.
- Goh KI, et al. The human disease network. Proc. Natl. Acad. Sci. USA. 2007;104:8685–8690. doi: 10.1073/pnas.0701361104.
- Menche J, et al. Disease networks. Uncovering disease–disease relationships through the incomplete interactome. Science. 2015;347:1257601–1257601. doi: 10.1126/science.1257601.
- Zhou, X., Menche, J., Barabási, A.-L. & Sharma, A. Human symptoms–disease network. Nat. Commun.5, 4212 (2014).
- Oettrich JM, et al. Clinical relevance of cyclic GMP modulators: a translational success story of network pharmacology. Clin. Pharmacol. Ther. 2016;99:360–362. doi: 10.1002/cpt.336.
- Erdmann J, et al. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature. 2013;504:432–436. doi: 10.1038/nature12722.
- Atochin DN, et al. Soluble guanylate cyclase alpha1beta1 limits stroke size and attenuates neurological injury. Stroke. 2010;41:1815–1819. doi: 10.1161/STROKEAHA.109.577635.
- Kemp-Harper B, Schmidt HHHW. cGMP in the vasculature. Handb. Exp. Pharmacol. 2009;191:447–467. doi: 10.1007/978-3-540-68964-5_19.
- Parker JO. Nitrates and angina pectoris. Am. J. Cardiol. 1993;72:3C–6C. doi: 10.1016/0002-9149(93)90248-B.
- Khot UN, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N. Engl. J. Med. 2003;348:1756–1763. doi: 10.1056/NEJMoa022021.
- Ghofrani HA, et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2013;369:330–340. doi: 10.1056/NEJMoa1209655.
- Stasch JP, Schlossmann J, Hocher B. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr. Opin. Pharmacol. 2015;21:95–104. doi: 10.1016/j.coph.2014.12.014.
- Sharina, I. G. et al. Alpha1 soluble guanylyl cyclase (sGC) splice forms as potential regulators of human sGC activity. J. Biol. Chem. 283, 15104–15113 (2008).
- Guney, E., Menche, J., Vidal, M. & Barabási, A.-L. Network-based in silico drug efficacy screening. Nat. Commun. 7, 10331 (2016).
- Wong D, Dorovini-Zis K, Vincent SR. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp. Neurol. 2004;190:446–455. doi: 10.1016/j.expneurol.2004.08.008.
- Kim TJ, Lee JS, Hong JM, Lim YC. Intracerebral steal phenomenon: a potential mechanism for contralateral stroke after carotid artery stenting. Neurologist. 2012;18:128–129. doi: 10.1097/NRL.0b013e318253f8b5.
- Friebe A, Koesling D. The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models. Nitric Oxide. 2009;21:149–156. doi: 10.1016/j.niox.2009.07.004.
- Semplicini A, Calò L. Administering antihypertensive drugs after acute ischemic stroke: timing is everything. CMAJ. 2005;172:625–626. doi: 10.1503/cmaj.1041393.
- Kleinschnitz, C. et al. NOS knockout or inhibition but not disrupting PSD-95-NOS interaction protect against ischemic brain damage. J. Cereb. Blood Flow Metab. 0271678X16657094. 10.1177/0271678X16657094 (2016).
- Ando H, et al. Localization of mRNAs encoding alpha and beta subunits of soluble guanylyl cyclase in the brain of rainbow trout: comparison with the distribution of neuronal nitric oxide synthase. Brain Res. 2004;1013:13–29. doi: 10.1016/j.brainres.2004.03.063.
- Nedvetsky PI, Kleinschnitz C, Schmidt HHHW. Regional distribution of protein and activity of the nitric oxide receptor, soluble guanylyl cyclase, in rat brain suggests multiple mechanisms of regulation. Brain Res. 2002;950:148–154. doi: 10.1016/S0006-8993(02)03015-9.
- Cote GJ, et al. Hydrogen peroxide alters splicing of soluble guanylyl cyclase and selectively modulates expression of splicing regulators in human cancer cells. PLoS. ONE. 2012;7:e41099. doi: 10.1371/journal.pone.0041099.
- Meurer S, et al. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ. Res. 2009;105:33–41. doi: 10.1161/CIRCRESAHA.109.198234.
- Kumar V, et al. Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes. Biochemistry. 2013;52:3601–3608. doi: 10.1021/bi301657w.
- Lapp H, et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009;119:2781–2788. doi: 10.1161/CIRCULATIONAHA.108.800292.
- Surapisitchat J, Jeon KI, Yan C, Beavo JA. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ. Res. 2007;101:811–818. doi: 10.1161/CIRCRESAHA.107.154229.
- Becker LC. Conditions for vasodilator-induced coronary steal in experimental myocardial ischemia. Circulation. 1978;57:1103–1110. doi: 10.1161/01.CIR.57.6.1103.
- Nakano T, et al. Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication. Brain Res. 2015;1624:330–335. doi: 10.1016/j.brainres.2015.07.027.
- Boutin H, et al. Role of IL-1alpha and IL-1beta in ischemic brain damage. J. Neurosci. 2001;21:5528–5534. doi: 10.1523/JNEUROSCI.21-15-05528.2001.
- Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat. Med. 2002;8:1363–1368. doi: 10.1038/nm1202-1363.
- Barone FC, et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke. 1997;28:1233–1244. doi: 10.1161/01.STR.28.6.1233.
- Basu A, et al. Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. J. Cereb. Blood Flow. Metab. 2005;25:17–29. doi: 10.1038/sj.jcbfm.9600002.
- Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J. Cereb. Blood Flow. Metab. 2012;32:1677–1698. doi: 10.1038/jcbfm.2012.88.
- Lee Y, et al. Therapeutically targeting neuroinflammation and microglia after acute ischemic stroke. Biomed. Res. Int. 2014;2014:297241–9.
- Kleikers PWM, et al. NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury. J. Mol. Med. 2012;90:1391–1406. doi: 10.1007/s00109-012-0963-3.
- Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002;35:605–623. doi: 10.1016/S0896-6273(02)00828-0.
- Paul C, Stratil C, Hofmann F, Kleppisch T. cGMP-dependent protein kinase type I promotes CREB/CRE-mediated gene expression in neurons of the lateral amygdala. Neurosci. Lett. 2010;473:82–86. doi: 10.1016/j.neulet.2010.02.020.
- Stasch JP, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 2006;116:2552–2561. doi: 10.1172/JCI28371.
- Evgenov OV, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug. Discov. 2006;5:755–768. doi: 10.1038/nrd2038.
- Ohigashi T, Brookins J, Fisher JW. Interaction of nitric oxide and cyclic guanosine 3′,5′-monophosphate in erythropoietin production. J. Clin. Invest. 1993;92:1587–1591. doi: 10.1172/JCI116740.
- Fedorov NA, Ermil’chenko GV, Malykhina IS, Borisov BN. Cyclic guanosine-3′,5′-monophosphate–mediator of the action of the hormaone erythropoietin. Dokl. Akad. Nauk. SSSR. 1977;233:985–988.
- Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM. Neuroprotective properties of epoetin alfa. Nephrol. Dial. Transplant. 2002;17 Suppl 1:8–12. doi: 10.1093/ndt/17.suppl_1.8.
- Villa P, et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J. Cereb. Blood Flow. Metab. 2007;27:552–563. doi: 10.1038/sj.jcbfm.9600370.
- Mengozzi M, et al. Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke. Proc. Natl. Acad. Sci. USA. 2012;109:9617–9622. doi: 10.1073/pnas.1200554109.
- Ehrenreich H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647–56. doi: 10.1161/STROKEAHA.109.564872.
- Gheorghiade M, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail. Rev. 2013;18:123–134. doi: 10.1007/s10741-012-9323-1.
- Ghosh A, et al. Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma. Proc. Natl. Acad. Sci. USA. 2016;113:E2355–62. doi: 10.1073/pnas.1524398113.
- Loscalzo, J., Kohane, I., Barabási, A.-L. Human disease classification in the postgenomic era: A complex systems approach to human pathobiology. Mol Syst Biol.3, 124 (2007).
- Ghiassian, S. D. et al. Endophenotype Network Models: Common Core of Complex Diseases. Sci. Rep.6, 27414 (2016).
- Kleikers PW, et al. A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation. Sci. Rep. 2015;5:13428. doi: 10.1038/srep13428.
- Hidalgo CA, Blumm N, Barabási AL, Christakis NA. A dynamic network approach for the study of human phenotypes. PLoS. Comput. Biol. 2009;5:e1000353. doi: 10.1371/journal.pcbi.1000353.
- Kleinschnitz C, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS. Biol. 2010;8:e1000479. doi: 10.1371/journal.pbio.1000479.
- Kleinschnitz C, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J. Exp. Med. 2006;203:513–518. doi: 10.1084/jem.20052458.
- Pham M, et al. Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by high-field MRI. Neuroimage. 2010;49:2907–2914. doi: 10.1016/j.neuroimage.2009.11.061.
- Stasch JP, et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br. J. Pharmacol. 2002;136:773–783. doi: 10.1038/sj.bjp.0704778.
- Brede M, et al. α(2)-adrenoceptors do not mediate neuroprotection in acute ischemic stroke in mice. J. Cereb. Blood Flow. Metab. 2011;31:e1–7. doi: 10.1038/jcbfm.2011.110.
- Connolly ES, Winfree CJ, Stern DM, Solomon RA, Pinsky DJ. Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. Neurosurgery. 1996;38:523–31.
- Bederson JB, et al. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 1986;17:1304–1308. doi: 10.1161/01.STR.17.6.1304.
- Moran PM, Higgins LS, Cordell B, Moser PC. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc. Natl. Acad. Sci. 1995;92:5341–5345. doi: 10.1073/pnas.92.12.5341.
- Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods. 1986;89:271–277. doi: 10.1016/0022-1759(86)90368-6.
- Chan SL, Fiscus RR. Guanylyl cyclase inhibitors NS2028 and ODQ and protein kinase G (PKG) inhibitor KT5823 trigger apoptotic DNA fragmentation in immortalized uterine epithelial cells: anti-apoptotic effects of basal cGMP/PKG. Mol. Hum. Reprod. 2003;9:775–783. doi: 10.1093/molehr/gag094.
Source: PubMed